In July and November of 2009 Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) announced positive 52-week data for BENLYSTA™ (belimumab) from two Phase 3 clinical trials, BLISS-52 and Bliss-76.
On April 20, 2010 HGS and GSK released topline secondary endpoints from the BLISS-76 clinical trial. BENLYSTA was successful in meeting the primary endpoint at 52 weeks for both the BLISS-52 and BLISS-76 trials. Some positive trends in the data did continue beyond a year; however, BENLYSTA did not meet its secondary endpoint at 76 weeks.
The LFA will continue to monitor BENLYSTA as additional data is released and it is submitted to the U.S. Food and Drug Administration for review.
Read the full HGS press release on the Topline 76-Week Results for BENLYSTA™.
Source
Lupus Foundation of America, Inc.
View drug information on Benlysta.